New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting

Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.